Home About Us Pipeline Partnerships Investors News & Events Careers Contact Us
S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values
Clinical Trials
News & Press Releases | Participation in Events | Publications
Join Our Team | Career Opportunities

The best scientist is open to experience and begins with romance - the idea that anything is possible.
Ray Bradbury


2010 News & Press Releases


07 December 2010 - S*BIO’s Oral Histone Deacetylase (HDAC) Inhibitor SB939 Shows Tolerability and Safety in Phase 1 Clinical Trial in Patients with Advanced Hematologic Malignancies
06 December 2010 - S*BIO’s Novel JAK2 Inhibitor SB1518 Is Shown to Be a Safe and Effective Therapy in Phase 1/2 Studies For Patients with Symptomatic Myelofibrosis and Relapsed/Refractory Lymphoma
22 November 2010 - Fourth Compound from S*BIO, Oral Multi-Kinase Inhibitor SB1317, Enters Phase 1 Clinical Trial in Advanced/Refractory Hematologic Malignancies
18 October 2010 - S*BIO’s JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
27 September 2010 - S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)
23 September 2010 - S*BIO Announces US$5 Million Investment by Mitsui Ventures
13 June 2010 - S*BIO Presents Positive Safety and Tolerability Results for its Novel Oral JAK2 Inhibitor SB1518 from a Phase 1/2 Study for the Treatment of Myelofibrosis (MF)
9 June 2010 - S*BIO Completes Enrollment of Patients in Phase 2 Clinical Trials for its JAK2 Inhibitor SB1518
4 May 2010 - S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors






Back to News

Back to top



Copyright © 2002-2011 S*BIO Pte Ltd. All rights reserved.